A New Drug Platform For Heart Disease And Diabetes

About this Event

Heart disease is the leading cause of mortality in the US. Due to its unique characteristics, heparin continues to be one of the most widely used drugs during cardiovascular procedures, (used 12 to 15 million times per year).

An allergic reaction from heparin (HIT) occurs in 300,000 patients in the US alone, which can result in stroke, amputation and death in up to 30% of affected patients.

Veralox’s lead program VLX-1005 targets the root cause of HIT via the 12-Lipoxygenase target and is being developed as a potential treatment. VLX-1005 has received orphan drug and fast-track designation from the FDA and has begun Phase 2 clinical sites that include Stanford and Yale.

Watch the webinar with Veralox CEO, Jonathan Mow to hear the full story and hear why Hatteras Venture Partners, Genesys Capital, Sanofi Ventures, JDRF T1D Fund, and others have all backed the company.

Video On Demand

– Recorded


All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.